Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2006 3
2008 6
2009 5
2010 6
2011 8
2012 10
2013 8
2014 7
2015 11
2016 10
2017 15
2018 17
2019 12
2020 23
2021 15
2022 18
2023 22
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

176 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
Solomon BJ, Bauer TM, Mok TSK, Liu G, Mazieres J, de Marinis F, Goto Y, Kim DW, Wu YL, Jassem J, López FL, Soo RA, Shaw AT, Polli A, Messina R, Iadeluca L, Toffalorio F, Felip E. Solomon BJ, et al. Among authors: soo ra. Lancet Respir Med. 2023 Apr;11(4):354-366. doi: 10.1016/S2213-2600(22)00437-4. Epub 2022 Dec 16. Lancet Respir Med. 2023. PMID: 36535300 Clinical Trial.
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301.
Cho BC, Ahn MJ, Kang JH, Soo RA, Reungwetwattana T, Yang JC, Cicin I, Kim DW, Wu YL, Lu S, Lee KH, Pang YK, Zimina A, Fong CH, Poddubskaya E, Sezer A, How SH, Danchaivijitr P, Kim Y, Lim Y, An T, Lee H, Byun HM, Zaric B. Cho BC, et al. Among authors: soo ra. J Clin Oncol. 2023 Sep 10;41(26):4208-4217. doi: 10.1200/JCO.23.00515. Epub 2023 Jun 28. J Clin Oncol. 2023. PMID: 37379502 Clinical Trial.
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT. Solomon BJ, et al. Among authors: soo ra. Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6. Lancet Oncol. 2018. PMID: 30413378 Clinical Trial.
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.
Rudin CM, Liu SV, Soo RA, Lu S, Hong MH, Lee JS, Bryl M, Dumoulin DW, Rittmeyer A, Chiu CH, Ozyilkan O, Johnson M, Navarro A, Novello S, Ozawa Y, Tam SH, Patil NS, Wen X, Huang M, Hoang T, Meng R, Reck M. Rudin CM, et al. Among authors: soo ra. J Clin Oncol. 2024 Jan 20;42(3):324-335. doi: 10.1200/JCO.23.01363. Epub 2023 Nov 17. J Clin Oncol. 2024. PMID: 37976444 Free PMC article. Clinical Trial.
Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis.
Liam CK, Ahmad AR, Hsia TC, Zhou J, Kim DW, Soo RA, Cheng Y, Lu S, Shin SW, Yang JC, Zhang Y, Zhao J, Berghoff K, Bruns R, Johne A, Wu YL. Liam CK, et al. Among authors: soo ra. Clin Cancer Res. 2023 May 15;29(10):1879-1886. doi: 10.1158/1078-0432.CCR-22-3318. Clin Cancer Res. 2023. PMID: 36971777 Free PMC article. Clinical Trial.
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.
Piotrowska Z, Tan DS, Smit EF, Spira AI, Soo RA, Nguyen D, Lee VH, Yang JC, Velcheti V, Wrangle JM, Socinski MA, Koczywas M, Janik JE, Jones J, Yu HA. Piotrowska Z, et al. Among authors: soo ra. J Clin Oncol. 2023 Sep 10;41(26):4218-4225. doi: 10.1200/JCO.23.00152. Epub 2023 Jun 29. J Clin Oncol. 2023. PMID: 37384848
Lung Cancer in Singapore.
Ang YLE, Chia PL, Chua KLM, Devanand A, Leong CN, Liew CJY, Ong BH, Samol J, Seet JE, Tam JKC, Tan DSW, Teo LLS, Soo RA. Ang YLE, et al. Among authors: soo ra. J Thorac Oncol. 2021 Jun;16(6):906-911. doi: 10.1016/j.jtho.2020.11.020. J Thorac Oncol. 2021. PMID: 34034887 Free article. No abstract available.
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, Riely GJ, Ou SI, Clancy JS, Li S, Abbattista A, Thurm H, Satouchi M, Camidge DR, Kao S, Chiari R, Gadgeel SM, Felip E, Martini JF. Shaw AT, et al. Among authors: soo ra. J Clin Oncol. 2019 Jun 1;37(16):1370-1379. doi: 10.1200/JCO.18.02236. Epub 2019 Mar 20. J Clin Oncol. 2019. PMID: 30892989 Free PMC article. Clinical Trial.
176 results